Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...

Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present ...

In the evolving landscape of artificial intelligence (AI), the assumption that more data lead to better models has driven unchecked reliance on synthetic data to augment training datasets. Although ...

Recursion Pharmaceuticals Inc's (NYSE: RXRX) short interest as a percent of float has fallen 15.85% since its last report.

In 2017, fresh off a PhD on theoretical chemistry, John Jumper heard rumors that Google DeepMind had moved on from building ...

We recently published 10 Big Names Crushing the Market. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the ...

At ELRIG’s 2025 meeting in GSK’s Stevenage campus, Recursion’s Executive Director of Computational Biology, Dr. Kelly ...

Dr. James McCaffrey presents a complete end-to-end demonstration of decision tree regression from scratch using the C# language. The goal of decision tree regression is to predict a single numeric ...

Is that the case? Let's look into it and decide whether the company is worth investing in.

Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week.